Literature DB >> 14636926

Comparison of survival in patients with pulmonary hypertension associated with fenfluramine to patients with primary pulmonary hypertension.

Stuart Rich1, Alicia Shillington, Vallerie McLaughlin.   

Abstract

To test whether the clinical presentation and prognosis of fenfluramine-induced pulmonary hypertension (PH) differs from primary PH (PPH), we compared the clinical profile and outcome of 10 patients with fenfluramine-induced PH with that of 70 patients with PPH referred to our center over the same time frame and treated identically. Patients with diet pill PH were similar to those with PPH with respect to hemodynamics. However, patients with fenfluramine-induced PH had poorer survival: 1-year survival 50% versus 88%, and 3-year survival 17% versus 60%.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14636926     DOI: 10.1016/j.amjcard.2003.08.034

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  2 in total

Review 1.  Epidemiology of pulmonary arterial hypertension.

Authors:  Xin Jiang; Zhi-Cheng Jing
Journal:  Curr Hypertens Rep       Date:  2013-12       Impact factor: 5.369

2.  Urantide improves the structure and function of right ventricle as determined by echocardiography in monocrotaline-induced pulmonary hypertension rat model.

Authors:  Yan Wang; Wei Tian; Chunhong Xiu; Ming Yan; Shuya Wang; Yifang Mei
Journal:  Clin Rheumatol       Date:  2018-01-23       Impact factor: 2.980

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.